Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Hims calculated the average price of a serving of eight protein-rich foods to determine the most cost effective way to add ...

The average weight for women in the U.S. is 170.8 pounds, and the average height is 5 feet, 3 inches tall. These are ...

Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

We recently published a list of AI Stocks Dominate Wednesday’s 10 Worst Performers. In this article, we are going to take a ...

Hims & Hers Health stock corrected after earnings because of the outlook on its key GLP-1 medication. See why I rate HIMS a ...

Health care companies slid as traders retreated from high-risk issues. Shares of obesity-drug maker Novo Nordisk and Hims & Hers Health, the compounding pharmacy seeking to compete with the ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Hims & Hers Health. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened ...